Mikhail Blagosklonny, a professor of Oncology, a researcher and a philanthropist who is enthusiastic about affordable health care. He carries out his professor duties at the Rosewell Park Cancer Institute in Buffalo, New York. He is also the editor-in-chief of Oncotarget where he has published many of his research works on cancer and aging. Mikhail Blagosklonny has continually stated his vision that quality and affordable healthcare should be made available to everyone regardless of their economic status.Mikhail Blagosklonny’s area of interest is focused studying the connection between cancer and aging. His research has been dedicated to finding out the reason why cancer is common in individuals who have reached a certain age. He has made numerous contributions to medical research in this area, in particular through his published work. His research topic has attracted a lot of attention in the medical field.He has been advocating for the use of cancer drug Rapamycin to increase the longevity of life in human beings. Rapamycin is better known by its brand name Rapamune and is famously used to treat cancer. It is usually used in organ transplant recipients to prevent rejection of the donor organs.
It is also employed in coronary stents as a coating to treat narrow or weak arteries. Rapamycin is also used to treat rare lung disease.Rapamycin, also known as Sirolimus was first Isolated by physicians in 1972. It was obtained from samples of a bacterium discovered on Easter Island. Sirolimus was initially being used as an anti-fungal agent, which significantly underutilized its potential. Later on, physicists found that this drug had multiple immunosuppressive and antiproliferative properties. This led to the diversification of the use of the drug in various treatment regimes and largely abandoned its initial use as an antifungal agent.Mikhail Blagosklonny continues to work towards his vision of finding out a different way of treating cancer. The professor of oncologist wants cancer treatment to be effective, less painful and several times cheaper than the current treatment regimes. He hopes to achieve this by coming up with a way to eliminate cancerous cells from the body without destroying the healthy cells as well.
The healthy cells are the ones responsible for regenerating and recovering the body after the characteristically prolonged cancer treatments.The professor has made tremendous progress in his field even though he has not yet made the breakthrough he is targeting. Mikhail Blagosklonny has hopes that his research findings will inspire other researchers and oncologists to continue with the pursuit in the same direction. He has expressed his optimism that in the future, cancer will not be as dangerous and expensive to treat. He instead envisions the fact that it will be easy and no longer a luxury to treat. Dr. Mikhail Blagosklonny has already made history by being a pioneer in the use of Rapamycin to deal with a broad range of illnesses. He has also been recognized for his rather unique but compelling advocacy that the human lifespan be increased scientifically with the help of rapamycin.
Eric Lefkofsky has decided to go into self-funding to establish a technology company that will use predictive data to combat cancer infections. Forbes estimates that is net worth is $1.7 billion, and he has promised to put most of the income into the Tempus cancer project. The company in which he is a co-founder and chief executive officer is setting up an operating system that will be used to diagnose and treat cancer. Before the latest venture, Eric Lefkofsky helped to establish many startups in the tech industry. He was the CEO of Groupon which provided a global marketplace for e-commerce besides being the principal of various prominent technology companies like Lightbanks.
He is the principal founder of technology companies in Chicago and together with his partner called Brad Keywell they have helped to transform many startups into success companies trading publicly. But the interest he had as a serial entrepreneur in tech ventures came to a rude stop when his wife was diagnosed with cancer. He was frank to admit that he was confused because of the severe diagnoses, and he said that could happen to anybody to know more: http://chicago.curbed.com/2015/1/6/10005148/groupon-ceo-eric-lefkofsky-the-man-behind-195m-home-sale click here.
The investor who is now 47 years old was however not amused by the fact that he could not get all the information Eric Lefkofsky needed about cancer. The lack of any clear direction made him come up with the idea of Tempus. The new company the two partners have established will be data-oriented to the management of cancer. By applying machine learning and sequencing of genomics, the operating system will provide a clearer relationship between the type of tumor and the patient so that so that the best treatment option can be applied.
He said the Tempus venture was one of the most ambitious things he has ever attempted in technology. He has left his partner to be the CEO of a startup predictive analytics known as Uptake while he is devoting his time to Tempus. He says the latest initiative will create a significant shift in paradigm in the technology industry like Facebook did for linking people or Google did for changing how people relate to the internet. He is deeply involved in philanthropy through the Lefkofsky Family Foundation.